CN103547275B - 用于调节外周免疫功能的方法和组合物 - Google Patents

用于调节外周免疫功能的方法和组合物 Download PDF

Info

Publication number
CN103547275B
CN103547275B CN201280024630.1A CN201280024630A CN103547275B CN 103547275 B CN103547275 B CN 103547275B CN 201280024630 A CN201280024630 A CN 201280024630A CN 103547275 B CN103547275 B CN 103547275B
Authority
CN
China
Prior art keywords
cells
cell
purposes
cytokine
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280024630.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103547275A (zh
Inventor
M·道
C·凯斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanbio Inc
Original Assignee
Sanbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanbio Inc filed Critical Sanbio Inc
Priority to CN201611001568.0A priority Critical patent/CN106692193B/zh
Publication of CN103547275A publication Critical patent/CN103547275A/zh
Application granted granted Critical
Publication of CN103547275B publication Critical patent/CN103547275B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
CN201280024630.1A 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物 Active CN103547275B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611001568.0A CN106692193B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161516637P 2011-04-06 2011-04-06
US61/516,637 2011-04-06
US201161541248P 2011-09-30 2011-09-30
US61/541,248 2011-09-30
PCT/US2012/032504 WO2012154344A1 (en) 2011-04-06 2012-04-06 Methods and compositions for modulating peripheral immune function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611001568.0A Division CN106692193B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Publications (2)

Publication Number Publication Date
CN103547275A CN103547275A (zh) 2014-01-29
CN103547275B true CN103547275B (zh) 2016-12-28

Family

ID=47139503

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280024630.1A Active CN103547275B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物
CN201611001568.0A Active CN106692193B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611001568.0A Active CN106692193B (zh) 2011-04-06 2012-04-06 用于调节外周免疫功能的方法和组合物

Country Status (6)

Country Link
US (6) US8785190B2 (enExample)
EP (1) EP2694080B1 (enExample)
JP (7) JP5932970B2 (enExample)
CN (2) CN103547275B (enExample)
CA (1) CA2832356C (enExample)
WO (1) WO2012154344A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785190B2 (en) 2011-04-06 2014-07-22 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
JP6023218B2 (ja) 2012-01-27 2016-11-09 サンバイオ，インコーポレイティド 血管新生及び血管発生を調節するための方法及び組成物
EP2849766B1 (en) 2012-05-16 2019-03-06 SanBio, Inc. Cells for use in the treatment of brain injury
CA2885414C (en) 2012-10-09 2018-05-01 Sanbio, Inc. Methods and compositions for treatment of retinal degeneration
CA2901653C (en) * 2013-03-01 2019-01-08 Gunther Eissner Protection of the vascular endothelium from immunologically mediated cytotoxic reactions with human cd34-negative progenitor cells
AU2014230014B2 (en) 2013-03-15 2019-11-14 Tigenix, S.A.U. Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC)
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN105985928A (zh) * 2015-02-10 2016-10-05 睿尔（天津）生物科技有限公司 一种增强间充质干细胞免疫调节能力的预处理培养方法
EP3261651B1 (en) * 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
EP3307346A4 (en) * 2015-06-15 2019-01-02 Vital Therapies, Inc. Composition and method for inducing anti-inflammatory response
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US10383895B2 (en) * 2016-02-18 2019-08-20 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by T regulatory cells
EP3463482B1 (en) 2016-06-07 2021-10-06 The Brigham and Women's Hospital, Inc. Methods relating to t peripheral helper cells in autoantibody-associated conditions
EP4353750A3 (en) 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
CN110382020A (zh) 2016-12-28 2019-10-25 桑比欧公司 细胞递送系统及操作细胞递送系统的方法
SG11202000555UA (en) 2017-06-21 2020-02-27 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
JP7664169B2 (ja) 2019-10-17 2025-04-17 テルモ株式会社 炎症性疾患を処置するための細胞培養物
CN111979186B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种快速高效体外扩增人间充质干细胞的方法及应用
CN116376828B (zh) * 2023-06-02 2023-08-11 成都云测医学生物技术有限公司 一种诱导CD4+T细胞生成Treg细胞的方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134409A2 (en) * 2008-04-30 2009-11-05 Sanbio, Inc. Neural regenerating cells with alterations in dna methylation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5932970Y2 (ja) 1979-09-29 1984-09-14 トキナ−光学株式会社 ズ−ム式交換レンズにおける焦点距離の表示装置
JPS5993639U (ja) 1982-12-11 1984-06-25 愛知電機株式会社 撹拌装置における内容物の自動排出，投入装置
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
CA2271248C (en) * 1996-11-07 2009-08-11 Jonathan Robert Lamb Use of a notch ligand in immunotherapy
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
EP1410018A1 (en) 2001-07-25 2004-04-21 Lorantis Limited Method for detecting modultators of notch signalling
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
EP2270146A1 (en) 2002-02-06 2011-01-05 Sanbio, Inc. Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
JP2007532112A (ja) 2004-04-12 2007-11-15 サンバイオ，インコーポレイティド ニューロン始原細胞特性を示す細胞
US20060216276A1 (en) 2005-03-07 2006-09-28 Mari Dezawa Use of materials for treatment of central nervous system lesions
WO2008102460A1 (en) 2007-02-23 2008-08-28 Sanbio Inc. Transplantation of bone marrow stromal cell-induced neural stem cells for promoting fuctional recovery after spinal cord injury
EP2175868B1 (en) * 2007-08-15 2017-12-20 SanBio, Inc. Bone marrow derived cells for use in treating neural degeneration
US10702554B2 (en) 2007-12-03 2020-07-07 Sanbio, Inc. Extracellular matrix from pluripotent cells
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
US8518397B2 (en) * 2009-08-14 2013-08-27 Case Western Reserve University Notch induced natural killer cell generation and therapeutic uses
US8785190B2 (en) 2011-04-06 2014-07-22 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US20120263681A1 (en) * 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134409A2 (en) * 2008-04-30 2009-11-05 Sanbio, Inc. Neural regenerating cells with alterations in dna methylation

Also Published As

Publication number Publication date
US11903972B2 (en) 2024-02-20
CN106692193B (zh) 2021-01-05
JP7267976B2 (ja) 2023-05-02
CA2832356C (en) 2017-12-19
USRE46382E1 (en) 2017-05-02
JP2023052777A (ja) 2023-04-12
CA2832356A1 (en) 2012-11-15
US20170232042A1 (en) 2017-08-17
JP2017149759A (ja) 2017-08-31
WO2012154344A1 (en) 2012-11-15
CN103547275A (zh) 2014-01-29
EP2694080B1 (en) 2018-03-14
CN106692193A (zh) 2017-05-24
US20130095084A1 (en) 2013-04-18
EP2694080A4 (en) 2014-09-03
JP2016135817A (ja) 2016-07-28
EP2694080A1 (en) 2014-02-12
US8785190B2 (en) 2014-07-22
JP7631387B2 (ja) 2025-02-18
US10543234B2 (en) 2020-01-28
US20140286918A1 (en) 2014-09-25
JP6981934B2 (ja) 2021-12-17
JP6134032B2 (ja) 2017-05-24
JP5932970B2 (ja) 2016-06-08
JP6392926B2 (ja) 2018-09-19
JP2025069383A (ja) 2025-04-30
US20200113944A1 (en) 2020-04-16
US20240139255A1 (en) 2024-05-02
JP2014510153A (ja) 2014-04-24
JP2019006790A (ja) 2019-01-17
JP2021001180A (ja) 2021-01-07
US9655927B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
JP7631387B2 (ja) 末梢免疫機能を調節するための方法及び組成物
Stanic et al. IL-10–overexpressing B cells regulate innate and adaptive immune responses
Deng et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1
CN103079579B (zh) T细胞介导的免疫病症的治疗
Chen et al. Gene delivery with IFN-γ-expression plasmids enhances the therapeutic effects of MSCs on DSS-induced mouse colitis
US20100055076A1 (en) Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression
AU2011274255A1 (en) Treatment of T-cell mediated immune disorders
CN108699524B (zh) 调节t细胞介导性疾病的预防或治疗用药剂学组合物
HK1233517B (zh) 用於调节外周免疫功能的方法和组合物
HK1233517A1 (en) Methods and compositions for modulating peripheral immune function
HK1233517A (en) Methods and compositions for modulating peripheral immune function
HK1191880A (en) Methods and compositions for modulating peripheral immune function
HK1191880B (en) Methods and compositions for modulating peripheral immune function
Comi et al. Human tolerogenic DC-10 modulate allo-specific T cell responses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191880

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1191880

Country of ref document: HK

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20140129

Assignee: Okonvision biomedical (Shanghai) Co.,Ltd.

Assignor: Aokangweishi biomedical (Hong Kong) Co., Ltd

Contract record no.: X2020990000354

Denomination of invention: Methods and compositions for modulating peripheral immune function

Granted publication date: 20161228

License type: Exclusive License

Record date: 20200717